Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems

“Takeda has made a generational promise to improve health, and for the last 10 years, our Global CSR Program has given our people a meaningful way to put that promise into practice,” said Giles Platford, president of the International Business Unit at Takeda. “Significant, sustainable impact takes more than a single investment. It requires working with local partners who understand the needs in their communities and can help strengthen the systems people rely on. We are proud to support this year’s awardees as they address the challenging effects of climate change on healthcare systems and patients.”

Takeda’s commitments to these new awardees in 2026 include:

• USD 6.4 million to Corus International. Linking climate-adaptive early warning, resilient service delivery and disaster preparedness aiming to protect the continuity of essential health services in Nepal.
  • “Climate shocks are reshaping where and when diseases strike, and too often the communities with the least warning are most impacted,” said Daniel V. Speckhard, President & CEO of Corus International. “Thanks to Takeda's generous support and partnership, Corus will help communities in Nepal predict outbreaks before they spread, strengthen health facilities against climate disasters, and equip communities to respond early. Together, we're building an early warning model that will be sustained by government and can be scaled beyond Nepal.”
     
• USD 6.1 million to Humanity & Inclusion Handicap International. Strengthening inclusive, climate-resilient health systems by increasing workforce capacity, community preparedness and accessible facility adaptation in Honduras and Peru.
• “We are honored to be selected as a Takeda Global CSR Program FY2026 awardee,” said Manuel Patrouillard, General Director of Humanity and Inclusion Handicap International. “This project makes a stronger alliance to support communities facing climate-related health risks, especially children, older adults, and people with disabilities across Honduras and Peru.”
   
• “Takeda's support gives us an excellent opportunity to put pharmacists right at the heart of how we respond to climate change and health,” said Prof. Christian Agyare, Vice Chancellor of KNUST. “Through PharmAdapt project we will train our pharmacists, prepare them for emergencies, and build standards that will last well beyond this project. This partnership means KNUST, supported by Takeda, can lead the way in creating practical tools and lessons that other countries across West Africa, and beyond, can learn from.”
   
• “I am deeply grateful for Takeda’s support. This partnership represents an important investment in the health and resilience of vulnerable communities in Egypt and Lebanon, helping pregnant women, newborns, and children access climate-resilient and environmentally sustainable health services,” said Barbara Hintermann, Director General of Tdh. “This collaboration will generate critical evidence on what works, helping to shape scalable solutions and inform policies that strengthen health systems and safeguard children’s future in an increasingly climate-affected world.”
• USD 5.1 million to Kwame Nkrumah University of Science and Technology (KNUST). Readying the pharmacy workforce as frontline workers, advancing climate-responsive care through capacity building and greener practices in Ghana.
• USD 4.6 million to Terre des hommes Foundation (TdH). Supporting the building of climate resilient primary healthcare through facility retrofits, early warning and community preparedness in Egypt and Lebanon.

About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects”, “forecasts”, “outlook” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States and with respect to international trade relations; competitive pressures and developments; changes to applicable laws and regulations, including drug pricing, tax, tariff and other trade-related rules; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals; the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits; and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at https://www.sec.gov/. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.